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Macrophages contribute to a continuous increase in blood pressure and kidney damage in hypertension, but their polarization
status and the underlying mechanisms have not been clarified. This study revealed an important role for M2 macrophages and
the YM1/Chi3l3 protein in hypertensive nephropathy in a mouse model of hypertension. Bone marrow cells were isolated from
the femurs and tibia of male FVB/N (control) and transgenic hypertensive animals that overexpressed the rat form of
angiotensinogen (TGM(rAOGEN)123, TGM123-FVB/N). The cells were treated with murine M-CSF and subsequently with
LPS+IFN-γ to promote their polarization into M1 macrophages and IL-4+IL-13 to trigger the M2 phenotype. We examined the
kidneys of TGM123-FVB/N animals to assess macrophage polarization and end-organ damage. mRNA expression was
evaluated using real-time PCR, and protein levels were assessed through ELISA, CBA, Western blot, and immunofluorescence.
Histology confirmed high levels of renal collagen. Cells stimulated with LPS+IFN-γ in vitro showed no significant difference in
the expression of CD86, an M1 marker, compared to cells from the controls or the hypertensive mice. When stimulated
with IL-4+IL-13, however, macrophages of the hypertensive group showed a significant increase in CD206 expression, an
M2 marker. The M2/M1 ratio reached 288%. Our results indicate that when stimulated in vitro, macrophages from
hypertensive mice are predisposed toward polarization to an M2 phenotype. These data support results from the kidneys
where we found an increased infiltration of macrophages predominantly polarized to M2 associated with high levels of
YM1/Chi3l3 (91,89%), suggesting that YM1/Chi3l3 may be a biomarker of hypertensive nephropathy.
1. Introduction
Recent studies have established a strong association between
immunoinflammatory processes, hypertension, and chronic
forms of kidney disease [1–4]. These pathologies are marked
by progressive renal fibrosis and ultimately organ failure
[5, 6]. Nephropathy in the wake of sustained hypertension
is the second leading cause of end-stage renal disease
Hindawi
Mediators of Inflammation
Volume 2019, Article ID 9086758, 14 pages
https://doi.org/10.1155/2019/9086758
(ESRD), a condition whose incidence is increasing worldwide
[7, 8]. Studies of both animal models of CKD and human
hypertension have revealed high levels of proinflammatory
cytokines and have exposed inflammation as the most signif-
icant factor in the progression of fibrosis, regardless of the
initial cause [9, 10]. Thus, immunoinflammatory mecha-
nisms are now recognized as crucial contributors to both
acute and chronic forms of kidney disease [3].
Hypertension is marked by an infiltration of immune
cells into the kidneys, vessel walls, perivascular regions, and
nervous system; simultaneously, there is a high release of
cytokines, a production of reactive oxygen species (ROS),
and an increase in the expression of adhesion molecules
[4, 11, 12]. These events are mediated by the innate and
adaptive immune systems and have been shown to contrib-
ute to the sustained elevation of blood pressure [4].
Several studies [9, 10, 11] have implicated macrophages
in the pathogenesis of hypertension. An elegant study by
Wenzel et al. [13] provided strong evidence that monocytes
and macrophages mediate angiotensin II- (Ang II-) induced
hypertension and vascular dysfunction.
Studies of hypertension have revealed that Ang II acti-
vates angiotensin II receptor type 1 (AT1R). Upon hemody-
namic injury, this leads to the recruitment of monocytes to
the vasculature, kidney, and heart [13–16]. After infiltration,
monocytes differentiate into at least two phenotypes: M1 or
M2 [17, 18].
M1 cells express high levels of proinflammatory cyto-
kines including interleukin-1 beta (IL-1β) and tumor
necrosis factor-alpha (TNFα) and produce high amounts of
ROS, which strongly promote microbicidal and tumoricidal
activity. In contrast, M2 macrophages, also known as
“alternatively activated,” have anti-inflammatory effects and
mediate tissue repair through the secretion of IL-10 and
transforming growth factor-beta (TGF-β) [19, 20].
The M2 response has been shown to depend on a
sustained stimulus. Persistent lesions also cause irreversible
fibrosis and the destruction of tissue [21, 22]. Studies have
shown that the M2 phenotype enters a prorepair stage with
the expression of chitinase-like protein-3 (YM1/Chi3l3) and
acquires pathogenic functions [23–26].
YM1/Chi3l3 is a marker expressed by M2 macrophages
in diverse tissues in the mouse and has been associated with
recovery and function restoration [27, 28]. This protein
displays chemotactic activity for T lymphocytes, bone
marrow cells, and eosinophils [29]. Here, we attempt to
determine whether the YM1/Chi3l3 marker has functions
in arterial hypertension and hypertensive nephropathy,
where its roles have not yet been clarified.
YM1/Chi3l3 exhibits a significant homology to microbial
chitinases and several “chitinase-like” proteins reported
recently (in tissues including human cartilage- (HC-) gp39,
human macrophage chitotriosidase, porcine smooth muscle
gp38k, and Drosophila DS-47) [30]. A recent study [31] has
shown that YKL-40 serve as a new biomarker for predicting
hypertension in a population of prehypertensive subjects.
As Ang II promotes macrophage recruitment [32, 33], we
decided to study the cells in a mouse model in which the
renin-angiotensin system could be controlled. Ang II arises
from the precursor angiotensinogen (AOGEN), making it
one of the most important factors in the regulation of human
blood pressure.
Mice lacking AOGEN presented drastic hypotension,
pathomorphological alterations in the kidney, and reduced
survival [34–36]. In contrast, transgenic mice overexpress-
ing the rat AOGEN gene (TGM(rAOGEN)123, TGM123-
FVB/N) developed hypertension, cardiac hypertrophy,
impaired heart function, high levels of albuminuria, and
pronounced fibrosis [34, 37, 38]. This suggests that besides
being a good model of arterial hypertension, this animal
model can also be used in studies of hypertensive nephrop-
athy. We hypothesized that macrophages of these hyperten-
sive animals from 10 to 12 weeks of age would be
predisposed to polarize to an M2 phenotype and high levels
of YM1/Chi3l3 would be found in their kidneys. This could
make the protein a marker for hypertensive nephropathy.
2. Materials and Methods
2.1. Animals. The study was approved by the Federal
University of São Paulo Ethics Committee (approval number
CEUA 2384220216 in 29/Feb/2016). 10- to 12-week-old
hypertensive (TGM123-FVB/N) male mice and normoten-
sive controls (FVB/N) were used in the experiments. Mice
overexpressing rat AOGEN (TGM(rAOGEN)123), originally
generated on NMRI background [37], were crossed with
FVB/N mice for 8 generations to transfer the rAOGEN
transgene to the FVB/N background and generate the
hypertensive model. The animals were maintained under
standardized conditions with an artificial 12 h dark-light
cycle and free access to food and water. Mice from the control
group (FVB/N) (n = 9) and hypertensive group (TGM123-
FVB/N) (n = 9) were euthanized by cervical dislocation; then,
the femurs, tibia, and kidneys were extracted.
The transgenic animals used in this study (TGM123-
FVB/N) are considered a valid model of arterial hypertension
and hypertensive nephropathy since they presented mean
blood pressure around 158mmHg in males and 132mmHg
in females and developed high levels of albuminuria and
pronounced renal fibrosis [34, 37, 38].
2.2. Cell Culture. Bone marrow-derived macrophages
(BMDM) were isolated from the femur and tibia of the
control (FVB/N) and hypertensive (TGM123-FVBN) male
mice. Cells were filtered using a Cell Steiner 70μm filter
(Corning, USA), and the flow-through cells were washed
twice with PBS by centrifugation at 300 g for 5min. Subse-
quently, cells were lysed with 0.83% NH4Cl (3min/4
°C) and
cultured in RPMI 1640 (Gibco) and DMEM High Glucose
Medium (Gibco) supplemented with 10% FBS (Gibco),
1% penicillin-streptomycin (Gibco), and murine M-CSF
(macrophage colony-stimulating factor) (PeproTech, USA).
The culture medium was refreshed on day 3 and maintained
until day 7 to promote BMDM differentiation. On day 8, the
cells were polarized to M1 by 10μg/ml IFN-γ (R&D Systems)
and 1mg/ml LPS (E. coli-LPS, Sigma-Aldrich, USA) and to
M2 by 10μg/ml IL-4 (R&D Systems) and 10μg/ml IL-13
(R&D Systems). After induction of polarization, cells were
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cultured for 48 h and thereafter used for the RNA extraction,
one well per condition per animal.
2.3. Real-Time Quantitative PCR. Real-time quantitative
PCR (qPCR) was used to evaluate the mRNA expression of
macrophage polarization marker genes. RNA isolation from
the kidney and the macrophage cultures was performed
using TRIzol (TRIzol Reagent, Invitrogen, Germany) accord-
ing to the manufacturer’s instructions. The RNA pellet was
resuspended in RNase-free water and kept at −80°C until
used. RNA concentration was quantified using spectropho-
tometry (NanoDrop, München, Germany), and 1μg of
RNA was taken for the synthesis of cDNA using M-MLV
Reverse Transcriptase (Invitrogen). The reaction product
was amplified using the GoTaq qPCR Master Mix (Promega;
Germany) by real-time quantitative PCR (ABI 7900HT Real-
Time PCR System, Applied Biosystems, Germany). The
gene-specific primer sequences are listed in Table 1.
2.4. Histology. Paraffinized sections of renal tissue (5μm
thick) were deparaffinized, rehydrated, and incubated with
1% sirius red in a saturated solution of picric acid for
60min. Unbound sirius red was removed by treating the
sections with acidified water and coverslipped using Eukit.
The sections were examined and photographed at a mag-
nification of 2x with a Keyence BZ-9000 microscope
Table 1: The gene-specific primer sequences.
Gene name Direction Primer sequence (5′-3′)
β-Actin
Forward CTG GCC TCA CTG TCC ACC TT
Reverse CGG ACT CAT CGT ACT CCT GCT T
iNOS
Forward CTG CTG GTG GTG ACA AGC ACA TTT
Reverse ATG TCA TGA GCA AAG GCG CAG AAC
F4/80
Forward CTTTGGCTATGGGCTTCCAGTC
Reverse GCAAGGAGGACAGAGTTTATCGTG
CD86
Forward TCT CCA CGG AAA CAG CAT CT
Reverse CTT ACG GAA GCA CCC ATG AT
TNFα
Forward CCC ACG TCG TAG CAA ACC AC
Reverse CAC AGA GCA ATG ACT CCA AAG TAG
IL-1β
Forward GGC TCA TCT GGG ATC CTC TC
Reverse TCA TCT TTT GGG GTC CGT CA
MMP-9
Forward ACG GAC CCG AAG CGG ACA TT
Reverse TTG CCC AGC GAC CAC AAC TC
IL-6
Forward TAGTCCTTCCTACCCCAATTTCC
Reverse TTGGTCCTTAGCCACTCCTCC
CD206
Forward CAA GGA AGG TTG GCA TTT GT
Reverse CCT TTC AGT CCT TTG CAA GC
Collagen I
Forward GAC ATG TTC AGC TTT GTG GAC CTC
Reverse GGG ACC CTT AGG CCA TTG TGT A
Fibronectin
Forward CCT ACG GCC ACT GTG TCA CC
Reverse AGT CTG GGT CAC GGC TGT CT
KIM-1
Forward TGT CGA GTG GAG ATT CCT GGA TGG T
Reverse GGT CTT CCT GTA GCT GTG GGC C
YM1
Forward CCC CTG GAC ATG GAT GAC TT
Reverse AGC TCC TCT CAA TAA GGG CC
TGF-β1
Forward CAA CAA TTC CTG GCG TTA CCT TGG
Reverse GAA AGC CCT GTA TTC CGT CTC CTT
MCP-1
Forward CTCACCTGCTGCTACTCATTC
Reverse TTACGGCTCAACTTCACATTCA
Collagen III
Forward TCCTAACCAAGGCTGCAAGATGGA
Reverse AGGCCAGCTGTACATCAAGGACAT
AT1a
Forward CAAGTCGCACTCAAGCCTG
Reverse CTCAGAACAAGACGCAGGC
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(Keyence, Germany). The quantification of fibrosis was
performed using the Keyence digital image analysis software
(Keyence BZII).
2.5. Protein Extraction. Kidney tissue (ca. 1 g) was homoge-
nized in extraction buffer containing phosphatases and
protease inhibitors 100mM Tris-HCl (pH 7.5), 1% Triton
X-100, 10% sodium dodecyl sulfate (SDS), 10mM EDTA,
100mM sodium fluoride, 10mM sodium pyrophosphate,
10mM sodium orthovanadate, 2mM phenylmethylsulfonyl
fluoride (PMSF), and 0.1mg aprotinin/ml at 14000 rpm by
40 minutes at 4°C. Protein concentrations were determined
by the Bradford assay (Bio-Rad Laboratories, Hercules, CA,
USA). Extracts were used for Western blotting, CBA, and
ELISA analysis.
2.6. Enzyme-Linked Immunosorbent Assay (ELISA). Renal
levels of IL-10, IL-1β, and TNFα were determined using
Quantikine Mouse ELISA kits (R&D Systems, MN, USA)
according to the manufacturer’s instructions.
2.7. Detection of TGF-β and YM1/YM2 by Western Blot
(WB). Proteins extracted from the mouse kidney were
submitted to SDS-PAGE (25μg of protein/well) and trans-
ferred to a PVDF membrane at 300mA, for 2 h, in ice-cold
buffer (3 g/l Tris, 14,4 g/l glycine, and 20% methanol). Mem-
brane blocking was executed overnight, at 4°C, in PBS-T
(137mM NaCl, 2.7mM KCl, 8.1mM Na2HPO4, 1.5mM
KH2PO4, 0.05% Tween-20, pH 7.2), containing 5% (m/v) of
bovine serum albumin (Sigma). The membrane was then
incubated with 1 : 1000 anti-TGF-β antibody (Cell Signaling
Technology, #3709) in PBS-T or anti-YM-1+YM-2 and
1 : 10000 (Abcam, #ab192029) in PBS-T+5% BSA overnight
at room temperature on a shaker. After washing the
membrane (three times, 10min), the secondary antibody
(anti-IgG rabbit, HRP-conjugated, Sigma, #A6154, 1 : 5000)
was added and incubation proceeded for 1 h on a shaker.
After three washes as above, the substrate SuperSignal West
Pico (Pierce) was used to detect the bands in an imager.
The antibodies were removed from the membrane with two
subsequent 10-minute incubations in mild stripping buffer
(15 g/l glycine, 1 g/l SDS, 10ml Tween-20, pH 2.2). The
membrane was washed twice (10min each) with PBS and
twice (5min each) in PBS-T, blocked as above, and incubated
for 2 h in PBS-T with the primary anti-β-actin antibody
(1 : 5000, raised in rabbit) used as a loading control. Second-
ary antibody incubation and detection of the bands were
performed as above. The densitometry was obtained using
the software Scion Image (Release Alpha 4.0.3.2), and relative
protein expression was determined by dividing TGF-β and
YM1/YM2 by β-actin densitometry data.
2.8. Cytokine Assessment in Kidney Sample (CBA). Levels of
concentrations of interleukin-6 (IL-6), Monocyte Che-
moattractant Protein-1 (MCP-1), Interferon-γ (IFN-γ),
and tumor necrosis factor (TNF) in a kidney sample were
measured using the BD™ CBA Mouse Inflammation Kit
(Becton Dickinson (BD), USA). Controls and samples were
processed according to the manufacturer’s instructions. The
results were normalized according to the total value of the
protein and expressed as pg/mg protein.
2.9. Immunofluorescence (IF). Immunofluorescence for
F4/80, iNOS, and YM1 was performed by incubating the sec-
tions with Alexa Fluor 594 (1 : 300, ThermoFisher, #A11007)
anti-mouse and Alexa Fluor 488 anti-rabbit (1 : 300, Thermo-
Fisher, #A11034) anti-mouse sections. The nuclei were
stained with DAPI (1 : 600, ThermoFisher, #D1306). The kid-
ney slices were incubated with primary mouse anti-F4/80
antibodies (1 : 500, Abcam, #ab6640) overnight at 4°C, rabbit
anti-iNOS (1 : 100, Abcam, #ab15323), and rabbit anti-
YM-1+YM-2, (1 : 10000, Abcam, #ab192029). Nonspecific
binding was controlled by the replacement of a negative
control by the primary antibody.
2.10. 3D Confocal Microscopy. Immunopositive signals were
detected by 3D confocal microscopy (Zeiss LSM 780,
Germany). The images were analyzed with ImageJ software.
The images were acquired employing a PlanNeofluar 40x
objective with 1.3 numerical aperture. DAPI, Alexa 594, and
Alexa 488 were excited with 405 nm, 594 nm, and 488nm
lasers, while emission was collected between 421 nm-
488 nm, 597nm, and 646nm and 498nm and 554 nm,
respectively. Slices on the Z plane were taken. The stacked
images were rendered at the maximum precision available,
and three-dimensional projection was performed using the
“surface” option (ZEN software, Carl Zeiss, Germany).
2.11. Statistical Analysis.Data are presented asmeans ± SEM.
The statistical analysis was performed with Prism software
(GraphPad Software, La Jolla, CA, USA). Multiple groups
were compared through a one-way analysis of variance
(ANOVA) followed by the Bonferroni post hoc test. The
two-group analysis was performed using Student’s t-test.
p values < 0.05 were considered statistically significant.
3. Results
3.1. The Macrophages of Hypertensive Animals Have a
Predisposition toward the M2 Phenotype. Initially, we cul-
tured macrophages extracted from the bone marrow of
hypertensive TGM123-FVB/N and control mice (FVB/N)
over 10 days. After in vitro stimulation, we observed no
differences in the expression of CD86 (an M1 marker)
between the groups (Figure 1(a)). The hypertensive group,
however, revealed a significant increase in the expression of
CD206 (M2 marker) compared to controls (Figure 1(b)). In
this group, the M2/M1 ratio reached 288% (Figure 1(c)).
These results showed that the macrophages of hypertensive
animals had a predisposition toward the M2 phenotype.
3.2. The Kidneys of Hypertensive Animals Show High Levels of
Collagen and Macrophage Polarization to the M2 Phenotype.
Histological examinations confirmed that hypertensive ani-
mals TGM123-FVB/N exhibited higher levels of collagen,
indicative of both interstitial and perivascular fibrosis, com-
pared to control animals (FVB/N) (Figures 2(a) and 2(b)).
We analyzed the association between F4/80 gene expres-
sion and the presence of macrophages in the kidneys of
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hypertensive and control mice, which revealed significant
differences in the hypertensive group (Figure 3(a)). Hyper-
tensive groups exhibited no increase in the expression of
AT1aR (Figure 3(b)), suggesting that the Ang II-AT1R
interaction tends to shift the M1/M2 balance toward
M2 predominance.
We evaluated the expression of genes related to the
polarization to M1 (iNOS, CD86, TNFα, IL-1β, MCP-1,
MMP-9, and IL-6). Statistically significant differences were
found for transcripts of iNOS, TNFα, and IL-1β (Figure 4).
However, these differences were smaller than twofold.
Karlen et al. [39] showed that real-time qPCR yields reliable
estimates only in cases when the relative expression is two-
fold or higher.
In addition, these gene expression data do not support
the results from measurements of protein levels, in which
we did not find a significant difference in the M1 marker
protein levels relative to the respective control groups. This
was the case for TNFα (Figures 5(a) and 6(a)), IL-1β
(Figure 5(b)), IL-6 (Figure 6(b)), IFN-γ (Figure 6(c)),
MCP-1 (Figure 6(d)), and iNOS (Figure 7(c)).
Next, we evaluated the expression of genes related to
polarization to the M2 phenotype (Arg-1, IL-10, type I
collagen, type III collagen, fibronectin, KIM-1, YM1, and
TGF-β1). Statistically significant differences were found for
the expression of YM1, TGF-β1, type I collagen, type III
collagen, fibronectin, and KIM-1 (Figure 8).
We verified this at the protein level for IL-10, where no
significant difference was again detected (Figures 8 and 9).
We confirmed the high levels of other M2 markers,
including TGF-β1 and YM1, by Western blot (Figures 10(a)
and 10(b)).
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Figure 1: The macrophages of hypertensive animals have a predisposition toward the M2 phenotype. Four mice for each group, 6 wells per
animal. (a) CD86 gene expression. Values were expressed as the mean ± SEM. ∗p < 0 05 compared to M0 groups and #p < 0 05 relative to
IL-4+IL-13 groups, with ANOVA followed by Bonferroni correction for multiple comparisons. (b) CD206 gene expression. Values
expressed as the mean ± SEM. ∗p < 0 05 compared to M0 groups, #p < 0 05 relative to LPS+IFN-γ groups, and §§p < 0 05 compared to
IL-4+IL-13 from control mice, with ANOVA followed by Bonferroni correction for multiple comparisons. (c) Ratio M2/M1. Values
are expressed as the mean ± SEM. ∗p < 0 05 compared to the control group with the t-test. The M2/M1 ratio reached 288%.
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Figure 2: High levels of collagen were found in the kidneys of the hypertensive group. (a) Picro sirius red stained renal paraffin sections (renal
cortex and medulla) of nonhypertensive control (C) and of rAOGEN transgenic hypertensive (H) mice at the age of 12 weeks. Light
microscopic images were taken using a Keyence microscope (BZ-9000). Yellow arrows represent the perivascular fibrosis and black arrows
the interstitial fibrosis. The scale bar = 300 μm. (b) Analysis and quantification of total fibrosis (interstitial and perivascular) were
performed on digital renal images using a Keyence BZII analyzer. Data were presented as the area of fibrosis in % of whole renal section
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3.3. High Levels of YM1/Chi3l3 Were Found in the Kidneys of
Hypertensive Animals. Alongside a general increase in F4/80
levels (Figure 7(a)), other M2 markers exhibited a sharp
rise of expression in hypertensive kidneys (Figures 7, 8,
10(a) and 10(b)).
In addition, quantitative immunofluorescence showed
a significant jump in the expression of YM1 in hyperten-
sive animals (Figure 7(b)) but no difference in the M1
marker gene iNOS (Figure 7(c)), as can be observed in
Figures 11(a)–11(d).
4. Discussion
Despite strong evidence that macrophage polarization
plays an important role in the development of hypertension
[9, 10, 11], few studies have addressed the role of these cells
in the disease. We carried out a study of the polarization of
these cells from hypertensive animals in vitro and in vivo,
with the aim of developing insights into their possible
functions in the kidney and roles in renal pathologies.
This study revealed an important role for M2 macro-
phages during hypertensive nephropathy. Our main finding
was that the kidneys of 10- to 12-week-old hypertensive
TGM123-FVB/N mice exhibited high levels of collagen,
indicative of perivascular and interstitial fibrosis and
confirming earlier studies on this model [34, 38]. These
symptoms were accompanied by an increase in the expres-
sion of marker genes for the M2 phenotype, suggesting that
hypertensive kidneys had undergone an infiltration of
macrophages polarized preferentially toward M2. This effect
reflected the results of our in vitro investigation, in which
macrophages from hypertensive animals also had a predispo-
sition toward the M2 type.
Ang II, a peptide hormone whose effects are similar to
those of proinflammatory cytokines, plays a key role in the
progression of chronic renal damage and may be involved
in the development of fibrosis [40–42]. This vasoactive
peptide activates mesangial and tubular cells and intersti-
tial fibroblasts, increasing the expression and synthesis of
extracellular matrix proteins. Studies have shown that
blocking Ang II action through ACE inhibitors and Ang
II receptor antagonists prevents proteinuria and fibrosis,
as well as the infiltration of inflammatory cells into the
kidneys [40, 41].
During disease, kidneys are infiltrated by neutrophils
and subsequently by monocytes, which differentiate into
macrophages and contribute to tubular injury [43]. Proin-
flammatory macrophages are known to contribute to the
initiation and progression of renal diseases [44–49], renal
injury related to cisplatin nephrotoxicity [50, 51], and renal
allograft injury [52, 53].
The main feature of renal fibrosis is an excessive produc-
tion and accumulation of ECM (extracellular matrix) pro-
teins, which leads to the formation of scar tissue and
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subsequently to renal dysfunction and organ failure [41, 54].
The implication is that M1 macrophages are responsible
for triggering the fibrotic process due to their release of
proinflammatory cytokines, which indirectly promote the
proliferation of myofibroblasts and the recruitment of
fibrocytes [21, 55].
TNFα is known to have an autocrine effect on the activa-
tion of macrophages [56] in a process which mediates kidney
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injury [57]. M1 macrophages release inflammatory media-
tors including ROS and TNFα, which augment an injury in
a positive feedback loop, to cause renal fibrosis [1, 21]. Stud-
ies have shown that M1 proinflammatory macrophages are
recruited into the kidney within the first hours after
ischemia-reperfusion-induced acute kidney injury [58–60],
whereas M2 anti-inflammatory macrophages predominate
at a later time.
In the hypertensive animal model studied in this work,
however, we found no increase in protein levels of TNFα,
IL-1β, IL-6, IFN-γ, MCP-1, and iNOS in the kidneys. Thus,
our data do not support the polarization of macrophages to
an M1 phenotype, suggesting that at this stage of hyperten-
sion, there is no renal inflammatory process. We also found
no increase in the expression of AT1R. Prior work in a model
of rats that develop hypertension has shown that the infusion
of Ang II increased the number of type 1 T helper (Th1)
cytokine IFN-γ-secreting cells and decreased type 2 T helper
(Th2) cytokine IL-4-secreting cells [61].
After the inflammatory phase orchestrated by the M1
phenotype, Th2 cytokines are produced and promote polari-
zation to the M2 phenotype, which is known to create an
anti-inflammatory environment [22, 43]. This response is
generally associated with the resolution of inflammation
and tissue healing. But when a lesion persists, these cells
assume prorepair functions and promote irreversible fibrosis
and the progressive destruction of renal tissue [21, 22].
M2macrophages are initially anti-inflammatory, although
the healing process depends on the termination of the initial
injury [62]. In chronic conditions, on the other hand, M2
can activate resident fibroblasts through the release of trans-
forming growth factor-beta (TGF-β), platelet-derived growth
factor (PDGF), vascular endothelial growth factor (VEGF),
insulin-like growth factor 1 (IGF-1), and galectin-3 [63, 64].
This suggests that the severity of fibrosis depends on the type
of polarization macrophages undergo and the persistence of
the inflammatory injury [21].
An elegant study by Ma et al. [65] suggested that after
blocking AT1R with losartan, Ang II polarized macro-
phages into the M2 phenotype with a high expression of
YM1/Chi3l3 and suppressed the expression of M1 markers
in WT animals. It is important to note that this occurred in
an obesogenic environment where the leanWT and AT1aKO
animals showed no change in YM1/Chi3l3 protein levels.
Here, in contrast, we showed for the first time that the
lean hypertensive animals presented macrophage polariza-
tion to the M2 phenotype with high levels of YM1/Chi3l3.
Our transgenic animals come from a hypertensive environ-
ment and exhibit an overexpression of AOGEN.
In inflammation, the RAAS appears to act in an antago-
nistic way involving two different situations regarding the
polarization of macrophages [9, 65], but the mechanisms
have yet to be clarified. The activation of RAAS by AT1R in
macrophages promotes the infiltration and activation of
macrophages polarized to the M1 phenotype [1, 9, 65]. A
systemic infusion of Ang II is known to induce the expression
of proinflammatory mediators, such as MCP-1, TNFα, and
IL-6, in vascular smooth muscle and kidney cells [66]. The
other situation is related to M2 macrophages induced by
Ang II stimulation. Moore et al. [32] confirmed Ang II-
induced aortic infiltration with Ly6Chi monocytes, but at
7-14 days, these cells began to express the M2 phenotype,
with increased CD206 and arginase. In addition, macrophage-
specific AT1R receptor deficiency exacerbates renal fibrosis
induced by a unilateral ureteral obstruction [67].
In light of the data from our experiments, we suggest
that at this stage of hypertension, elevated AOGEN levels
contribute to the development of renal damage toward the
predominance of the M2 phenotype. In our experiments,
we did not block AT1aR, but the animals presented ele-
vated levels of AOGEN, and it seems that the AT1aR in
the kidneys from the hypertensive animals were not acti-
vated. This fact suggests that the hypertensive environment
plus the increase of AOGEN contributes to M2 macrophage
polarization. However, we cannot state that Ang II is the
mediator of M2 macrophage polarization (Figures 3 and 12)
in our animal model, since other members of the RAAS may
be involved.
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Some M2 markers, such as YM1/Chi3l3 from mice, were
first identified as proteins that were secreted during infec-
tions by parasites and allergic inflammations [29, 68, 69].
It is known that YM1/Chi3l3 is a marker specific for the
M2 macrophage phenotype [65], but little is known about
its function in arterial hypertension and hypertensive
nephropathy.
In this analysis, it has recently been shown that YKL-40, a
member of the chitinase protein family, found in humans
and homologous to YM1/Chi3l3, is positively associated with
the incidence of hypertension among prehypertensive
patients. The case-control study by Xu et al. [31] included
an extraction of plasma samples from 20343 prehypertensive
or normotensive Chinese subjects. This study suggested that
YKL-40 may be a new biomarker for predicting hypertension
in the prehypertensive population.
The analysis of the kidneys of our 10- to 12-week-old
hypertensive mice revealed a chronic activation of macro-
phages with an M2 phenotype. In addition, we found signif-
icant increases in levels of YM1/Chi3l3 protein (91,89%) and
collagen depositions.
Previous experiments by our group verified that the
YM1/Chi3l3 gene was expressed in the hearts of these
animals (unpublished data) but did not find significant dif-
ferences in the hypertensive group compared to the control
group at this stage. This suggests that at this point in the
development of arterial hypertension, this protein is found
in the kidney, but not in the heart of these animals, and
may serve as a marker specific for hypertensive nephropathy.
Our data support the idea that M2 macrophages help
promote the development of kidney fibrosis at a specific stage
of hypertension; this is in agreement with studies [70, 71]
pointing to macrophages as sources of profibrotic factors.
TGF-β1 has already been identified as a central mediator of
renal fibrosis [72–74] and plays an important role in the
progression of CKD.
In contrast, studies of experimental kidney disease
models have produced a body of evidence indicating a
multifunctional role of TGF-β in inducing both profibrotic
and protective effects [54]. This study did not reveal any
protective effects from TGF-β1. On the contrary, our work
suggests that high levels of TGF-β1 may be involved in the
development of fibrosis.
This work also revealed that the kidneys of hypertensive
animals experienced no change in IL-10. This cytokine is
produced by several cell types, including macrophages, which
polarize to an M2 phenotype, modulate the inflammatory
response, and promote tissue repair [60, 75]. IL-10 is also
known as an antifibrotic cytokine that is downregulated in
CKD [76].
IL-10 controls inflammatory processes by suppressing
the production of proinflammatory cytokines such as IL-1β
and TNFα, which are known to be regulated by NF-κB tran-
scription [77–79]. In general, IL-10 improves vascular and
renal functions in hypertension [80], although little has been
reported on the effects of this cytokine on hypertension,
particularly in immune environments that favor the develop-
ment of fibrosis. Our work suggests that basal levels of IL-10
do not represent a form of protection against renal fibrosis in
the hypertensive animals (Figure 12).
In conclusion, our work shows for the first time that
hypertensive animals are predisposed to a polarization of
macrophages to an M2 phenotype in vitro, revealing features
that suggest a profibrotic profile. This fits with our findings
that the kidneys of these hypertensive animals showed a high
deposition of collagen, accompanied by an increase in the
expression of macrophage markers with a clear predomi-
nance toward the M2 phenotype. Taken together, these data
suggest that M2 macrophages, associated with high levels of
YM1/Chi3l3, are linked to renal damage and fibrosis. Fur-
thermore, it suggests that YM1/Chi3l3 may serve as a new
biomarker of hypertensive nephropathy.
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Figure 10: Levels of M2 marker proteins. M2 macrophages produced high levels of YM1 protein (91,89%): (a) renal levels of YM1/YM2/
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Future studies are needed involving both YM1/Chi3l3
in mice and YKL-40 in humans at different time points
to confirm whether reducing levels of these proteins may
be beneficial in delaying the development of hypertensive
nephropathy.
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Figure 11: Immunofluorescence images of renal tissue showed colocalization between the F4/80, a macrophage marker, and YM1, suggesting
that high levels of the YM1 protein were secreted by M2 macrophages. On the other hand, there was no increase in iNOS, an M1
marker: (a) DAPI, iNOS, and F4/80 by IF; (b) 3D overlapping images of DAPI, iNOS, and F4/80 by IF; (c) panel of DAPI, YM1,
and F4/80 by IF; (d) 3D overlapping images of DAPI, YM1, and F4/80 by IF. The scale bar = 5μm.
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Figure 12: Macrophage polarization in the kidneys of 10- to 12-week-old hypertensive mice. The hypertensive stimuli from RAAS, as high
levels of AOGEN contributed to macrophage polarization in the kidneys of hypertensive mice with a clear predominance of the M2
phenotype. The high levels of TGF-β1 may be involved in the development of fibrosis. Basal levels of IL-10 do not represent a form of
protection against renal fibrosis in the hypertensive animals. In addition, at this stage of hypertension, our data do not support the
polarization of macrophages to an M1 phenotype. It seems that the AT1aR in the kidneys from the hypertensive animals were not
activated. High levels of AOGEN plus the hypertensive environment contribute to the M2 macrophage polarization. M2 macrophages
produced high levels of YM1/Chi3l3 protein (91,89%).
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